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Abstract
CD8 T cells protect the host from disease caused by intracellular pathogens, such as the Toxoplasma gondii (T. gondii)
protozoan parasite. Despite the complexity of the T. gondii proteome, CD8 T cell responses are restricted to only a small
number of peptide epitopes derived from a limited set of antigenic precursors. This phenomenon is known as
immunodominance and is key to effective vaccine design. However, the mechanisms that determine the immunogenicity
and immunodominance hierarchy of parasite antigens are not well understood. Here, using genetically modified parasites,
we show that parasite burden is controlled by the immunodominant GRA6-specific CD8 T cell response but not by
responses to the subdominant GRA4- and ROP7-derived epitopes. Remarkably, optimal processing and immunodominance
were determined by the location of the peptide epitope at the C-terminus of the GRA6 antigenic precursor. In contrast,
immunodominance could not be explained by the peptide affinity for the MHC I molecule or the frequency of T cell
precursors in the naive animals. Our results reveal the molecular requirements for optimal presentation of an intracellular
parasite antigen and for eliciting protective CD8 T cells.
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Introduction
CD8 T cells play a critical role in immune-mediated protection
against intracellular apicomplexan parasites. Antigenic determi-
nants recognized by CD8 T cells are short peptides of 8 to 10
amino acids presented by class I molecules of the major
histocompatibility complex (MHC I). Antigenic peptides are
typically degraded by cytosolic proteasomes, transported into the
endoplasmic reticulum (ER), trimmed by ER-resident aminopep-
tidases and loaded on peptide-receptive MHC I molecules [1].
The spectrum of peptides that can theoretically be presented by a
given MHC I is far larger than the peptides that actually elicit
CD8 T cell responses. Furthermore, not all the peptide-MHC I
complexes that can be recognized are equal: rather they elicit a
hierarchy of specific CD8 T cells. This phenomenon of ‘‘selection
and ranking’’ is termed immunodominance. Immunodominant
peptide-MHC I elicit the most abundant cognate T cell
populations, whereas subdominant peptide-MHC I induce less
abundant T cells (reviewed in [2,3]). Knowledge of the
mechanisms that enhance immunogenicity and determine im-
munodominance hierarchy is central to design of optimal
vaccines.
Mechanisms of immunodominance have been widely studied in
the context of viral infections. The dominant position in the
hierarchy has been positively correlated with 1) efficiency of
peptide generation by the antigen processing pathway, e.g. due to
proteasomal activity [4], ER aminopeptidase activity [5] or the
nature of epitope-flanking sequences [6]), 2) antigen abundance
[7], 3) ability of the antigen-presenting cells (APCs) to stimulate T
cells, e.g. dendritic cells (DCs) versus non-professional APCs [8], 4)
MHC binding affinity [4,9] and 5) size of the naı¨ve pool of specific
T cells [9,10,11]. This latter parameter is increasingly being
considered as a good predictor of immunodominance hierarchy,
although, like the other parameters, it does not seem to be absolute
[12].
During infection by intracellular parasites, the parameters that
promote immunogenicity of a protein and that determine T cell
immunodominance remain largely unknown. Unlike viruses,
parasite-derived antigens are not synthesized by the host cell
translation machinery, thus bypassing a preferential linkage
between protein synthesis and MHC I presentation [13].
Moreover, except for antigens that may be directly injected into
the host cytoplasm (e.g. T. gondii rhoptry proteins), most antigens
from parasites that live in vacuoles are segregated from the cytosol
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by one or more membranes. We hypothesize that, despite the
greater genomic complexity of apicomplexan parasites relative to
viruses [14], these key differences could determine the limited
number of hitherto characterized antigenic peptides from Plasmo-
dium yoelii [15] Theileria annulata [16] or T. gondii [17] parasites.
In the present study, we addressed the causes and consequences
of immunodominance during T. gondii infection. T. gondii is a
widespread intravacuolar parasite that can cause severe disease in
humans [18]. T. gondii replicates in a specialized parasitophorous
vacuole (PV) and CD8 T cells play a protective role, especially
against toxoplasmic encephalitis which is caused by the persistence
of cysts in the brain [19]. We previously identified a decamer
peptide (HF10, derived from the GRA6 protein) presented by the Ld
MHC I molecule and recognized by a large CD8 T cell population
during toxoplasmosis [17]. Two other epitopes, also presented by
Ld, have been reported: the ROP7-derived IF9 and the GRA4-
derived SM9 peptides [20]. Although the source antigens for each of
these epitopes are contained in T. gondii secretory organelles, the
GRA6-specific response appeared immunodominant based on its
magnitude [17]. The molecular mechanisms for the potent
immunogenicity of GRA6-derived HF10 epitope are not known.
We generated transgenic parasites that do or do not express the
GRA6-derived HF10 epitope and established that even in the
absence of the immunodominant GRA6-specific CD8 T cell
response, the subdominant GRA4 and ROP7 responses remain
poorly immunogenic and fail to protect mice from toxoplasmosis.
We show that the location of the epitope at the C-terminus of the
GRA6 antigenic precursor is a critical parameter that allows
efficient processing, determines immunodominance and provides
protection during chronic stage.
Results
A transgenic model to investigate parasite
immunogenicity
In order to study the pathophysiological consequences of HF10
immunodominance, we generated parasites that do or do not
express the GRA6-derived HF10 epitope. We took advantage of
the genetic diversity among three common T. gondii strains (type I,
II and III). While the GRA4-derived SM9 and ROP7-derived IF9
peptides are conserved (data not shown and ToxoDB.org), the
GRA6-derived HF10 peptide is polymorphic between type II and
type I/III strains. Within the last 10 residues of GRA6, four non-
synonymous single-nucleotide polymorphisms differentiate the
type II sequence (HF10: HPGSVNEFDF) from the type I/III
sequence (HY10: HPERVNVFDY) (Fig. 1A and Fig. S1 in Text
S1). We noted that instead of a phenylalanine (F), the C-terminal
residue in GRA6III is a tyrosine (Y), a residue not expected to be
an appropriate anchor residue for Ld binding [21]. To evaluate the
ability of HF10 and HY10 to bind to Ld, we used an MHC I
stabilization assay. TAP-deficient RMA-S cells display empty,
unstable MHC I molecules and addition of exogenous peptides
that can bind to MHC I can stabilize their expression on the cell
surface, as read out by flow cytometry. Expression of Ld on the
surface was stabilized by addition of HF10 at a 1000-fold lower
concentration compared to HY10 (Fig. 1B), which confirmed its
poor Ld binding capacity.
Given that a type III strain like CEP, expresses HY10 (and not
HF10), we inferred that it would provide a useful ‘‘HF10-null’’
background to analyze immunodominance in vivo. Therefore we
engineered CEP parasites to stably express type II or (as a control)
type I versions of GRA6 (designated CEP+GRA6II and CEP+
GRA6I respectively). To facilitate tracking of parasites and
infected cells, we used a CEP strain previously modified to express
the GFP and the luciferase reporter genes [22]. We assessed the
amount of transgenic GRA6 protein expressed by CEP+GRA6II
and CEP+GRA6I parasites by immunoblot, using an antibody
that detects all forms of GRA6 (I, II and III). The slower migration
of GRA6II allowed us to discriminate between endogenous
GRA6III and transgenic GRA6II. We confirmed expression of
GRA6II, at slightly higher levels as compared to endogenous
GRA6III in the same parasites. Transgenic GRA6I and endoge-
nous GRA6III were undistinguishable thus precluding a precise
analysis of the GRA6I transgene level. (Fig. 1C). Next, we infected
B10.D2 mice (H2d MHC haplotype) with CEP+GRA6II and
CEP+GRA6I parasites and 3 weeks post-infection, we measured
the CD8 T cell response induced by HF10 and HY10 peptides. As
observed with the type II Pru strain [17], nearly 25% of CD8 T
cells from CEP+GRA6II-infected spleens produced IFN-c in
response to HF10 peptide. In contrast, no response was detected
above background in CD8 T cells from CEP+GRA6I-infected
mice after restimulation with the HF10 or HY10 peptides (Fig. 1D).
We conclude that CEP strains are ‘‘HF10-null’’ and suitable for
assessing the immunogenicity of various transgenes.
Strong immunodominance of HF10 response but no
immunodomination over IF9 and SM9 responses
We used these transgenic parasites to confirm the immunodo-
minance hierarchy among the 3 known natural peptides presented
by Ld and to analyze the consequences of HF10 absence on T cell
responses to the other antigens. Four weeks post-infection, we
examined the T. gondii-specific CD8 T cell response in the spleen
using peptide-loaded Ld dimers (Fig. 2A). As expected, a large
fraction of HF10-specific CD8 T cells were detected only in
CEP+GRA6II-infected mice (9.5%+/23.7%, mean +/2 s.d.,
p = 1024). The IF9-specific CD8 T cells were found at a much
lower frequency (0.9+/20.8%, p = 0.11) and SM9-specific CD8 T
cells were hardly detectable. Interestingly, even in the absence of
HF10 (such as in CEP+GRA6I-infected mice), the frequencies of
IF9- and SM9-specific CD8 T cells did not increase, suggesting
that the subdominant status of IF9 and SM9 was not the result of
Author Summary
Toxoplasma gondii is a widespread intracellular parasite
that can cause severe disease in immunocompromised
individuals and lead to fetal abnormalities if contracted
during pregnancy. Establishment of protective immunity
relies on CD8 T cells, which recognize antigenic peptides
presented by MHC class I molecules on the surface of T.
gondii-infected cells. Intriguingly, while the proteome of
T. gondii is large, CD8 T cell responses target a very
limited set of peptides. These peptides can be ranked
according to the magnitude of the associated CD8
response (from immunodominant down to subdomi-
nant). Yet, little is known about the rules that define their
immunogenicity and the hierarchy of the associated T
cell responses. Using a panel of genetically modified T.
gondii where the GRA6 dominant antigen was mutated,
we show that the C-terminal location of the epitope
within the source antigen is the critical parameter for
immunodominance. Interestingly, when placed at the C-
terminus of GRA6, the subdominant status of an epitope
can be overturned. Our results unravel the mechanisms
that make parasite antigens accessible for the MHC I
presentation pathway. They may help to ameliorate
natural immune responses and improve vaccine design
against intravacuolar pathogens.
Epitope Location Controls Protection to T. gondii
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competition (also called immunodomination) exerted by HF10-
specific T cells. Similar results were obtained when we assessed
IFN-c production by effector CD8 T cells following in vitro
restimulation (Fig. 2B). Likewise, the epitope-specificity of CD8 T
cells in brain infiltrates showed the same HF10.IF9.SM9
hierarchy (Fig. 2C).
While the above experiments define the immunodominance
hierarchy among already known epitopes, unknown epitopes
could also play a role in the parasite-specific response. To analyze
the entire repertoire of T. gondii-specific CD8 T cells, we used
parasite-infected, rather than peptide-pulsed, APCs to restimulate
T cells ex vivo. The magnitude of IFN-c response elicited by
parasite-infected macrophages (Fig. 2D) was no higher than that
observed after peptide restimulation (see Fig. 2B). Thus, CD8 T
cells of other specificities do not play a major role in our
experimental model system.
Figure 1. Type III transgenic T. gondii to study parasite immunogenicity. (A) Schematics of GRA6 protein from type I/III and type II T. gondii.
C-terminal amino acid sequence is shown. (B) Surface labeling of peptide-loaded Ld analyzed by flow cytometry on TAP-deficient RMA-S.Ld cells left
unpulsed or pulsed with increasing concentrations of HF10, HY10 or a control Dd-restricted AI9 peptide. Shown is the mean fluorescence intensity
(MFI) in arbitrary units (a.u.). Data representative of 2 independent assays. (C) Western blot analysis of GRA6 (upper panel) and SAG1 (lower panel) in
type II Prugnaud (Pru), control CEP (a resistant HXGPRT+ clone which did not integrate the transgene), CEP+GRA6II and CEP+GRA6I clones. Data
representative of 4 independent experiments. (D) Ex vivo IFN-c intracellular staining of splenocytes from B10.D2 mice 3 weeks post-infection with
CEP+GRA6II (upper plots) or CEP+GRA6I (lower plots), restimulated in vitro with HY10 or HF10. Numbers represent the percentage of IFN-c+ out of
CD8+ cells. Plots show one representative mouse out of 3 per group.
doi:10.1371/journal.ppat.1003449.g001
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Taken together, our data demonstrate that the presence of
GRA6II in the parasites triggers a strong and dominant HF10-
specific CD8 response in the spleen and brain of chronically
infected animals but does not negatively affect (‘‘immunodomi-
nate’’) the subdominant SM9 and IF9 responses.
Expression of HF10 epitope results in diminished parasite
burden
We have previously reported that immunization of H2d mice
with HF10-loaded bone marrow-derived dendritic cells protects
against lethal type II parasite challenge [17]. We predicted that
presence of HF10 may decrease parasite burden. To test this
hypothesis, we took advantage of the luciferase expression to
analyze parasite dissemination by bioluminescence imaging in
BALB/c mice (H2d). Regardless of the presence of HF10, all
strains were cleared by day 13 (Fig. 3A,B). CEP+GRA6II parasites
appeared to be cleared slightly earlier than control CEP
(HXGPRT+) and CEP+GRA6I parasites, although this difference
did not reach statistical significance (Fig. 3A,B). In addition,
parasite signal in the brain was detected only in mice infected with
control CEP or CEP+GRA6I and was never observed with
CEP+GRA6II (Fig. S2 in Text S1). This suggested that the control
of parasitemia by HF10-specific T cells may be more effective at
the chronic stage, when parasites are found mostly as brain cysts.
When we measured parasitemia in chronically infected B10.D2
mice at 4 weeks post-infection, we found a significantly higher
proportion of splenocytes harboring parasites in CEP+GRA6I-
infected mice (Fig. 3C). Accordingly, the number of brain cysts in
CEP+GRA6I-infected mice was nearly 5 times higher than in mice
infected with the HF10-expressing parasites (Fig. 3D). These
results could not be attributed to an intrinsic growth difference
between clones since they behaved comparably in a plaque assay in
vitro (Fig. S3A in Text S1). Furthermore, the influence of HF10 on
cyst number was visible only in B10.D2 mice and not in C57BL/6
mice, which have a different MHC haplotype (H2b) and therefore
do not elicit HF10-specific T cells (Fig. S3B in Text S1).
Combined, the data show that the HF10-specific response has a
modest protective effect on parasite control during acute
toxoplasmosis but is essential for controlling parasite load during
chronic infection.
Peptide affinity for Ld and naı¨ve T cell frequency cannot
explain HF10 immunodominance
To uncover possible causes of HF10 immunodominance, we
used the MHC I stabilization assay described above (see Fig. 1B)
and compared the affinity for Ld of HF10 to other Ld-restricted
peptides. These other peptides were derived either from T. gondii
(SM9, IF9), from a mouse minor antigen (QL9) or from a mouse
cytomegalovirus protein (YL9) (Fig. 4A). HF10 affinity appeared
,10-fold higher than that of IF9, QL9 and YL9 but fell in the
same range as the T. gondii subdominant peptide SM9. Therefore,
the dominance hierarchy did not correlate with peptide affinity for
MHC I.
We next assessed whether abundance of peptide-specific T cells
in the repertoire of naı¨ve mice may control immunodominance.
We employed a tetramer-based enrichment procedure [23,24] to
enumerate naı¨ve T cells isolated from spleen and lymph nodes of
uninfected mice and specific for each of the 3 epitopes. Numbers
of T cell precursors were analyzed by flow cytometry after gating
on a population of live dump2 (dump = B220, F4/80, MHC II)
CD3+ CD8a+ cells (Fig. S4 in Text S1). Surprisingly, we observed
an inverse correlation between the number of naı¨ve T cells per
mouse and the immunodominance (Fig. 4B), with the frequency of
HF10-specific CD8 T cells around 10- and 3-fold lower than
SM9- and IF9-specific CD8 T cells respectively (Fig. 4C). Thus the
immunodominance of HF10 cannot be explained by a high
starting precursor frequency of specific T cells.
Location of HF10 at GRA6 C-terminus determines
presentation efficiency and parasite control
Having ruled out two plausible hypotheses, we wondered
whether HF10 immunodominance might be related to processing
efficiency. We noted that HF10 is located at the very C-terminus
of GRA6II, a position that may facilitate processing since no C-
terminal cut is required. To test the importance of epitope
position, we changed the C-terminus of HF10 by extending
GRA6II with one or more amino acids.
We first transfected C-terminally extended versions of GRA6II
in mouse fibroblasts. Extensions were either single amino acids
(lysine, K ; leucine, L ; proline, P) or several residues such as the
GRA6I/III-derived HY10 peptide or the entire GFP. We used
CTgEZ.4 T cell hybridomas, a b-galactosidase-inducible reporter
cell line [17], to read-out HF10 presentation. The response of
CTgEZ.4 T cells was mildly decreased (GRA6II-K), severely
disrupted (GRA6II-L) or totally abrogated (GRA6II-P, GRA6II-
HY10, GRA6II-GFP) (Fig. 5A). These data suggest that the C-
terminal location determines optimal processing and presentation
of the HF10 peptide when the precursor protein is expressed
ectopically by the antigen-presenting cell.
To assess the impact of HF10 position in T. gondii, we used CEP
parasites expressing longer versions of GRA6II, extended either by
a leucine (GRA6II-L) or by the HA tag (GRA6II-HA). First, we
verified that transgene levels were comparable by Western blot
(Fig. 5B). To investigate whether these additional C-terminal
residues might perturb GRA6 transport, we took advantage of the
HA tag and evaluated the subcellular distribution of transgenic
GRA6-HA, as compared to total GRA6. Analysis of the overlap
between HA and the GRA2 and GRA5 dense granule proteins in
extracellular tachyzoites (Fig. S5A,B in Text S1) and in infected
fibroblasts (Fig. S5C,D in Text S1), indicated that GRA6II-HA is
packaged in the dense granules and secreted in the vacuolar space,
as known for wild-type GRA6 [25]. Although the distribution of
GRA6II-L could not be directly assessed, we inferred from the
above data that the extra leucine did not alter protein transport
either. When used to infect bone marrow-derived macrophages
(BMDMs), the CEP+GRA6II-L and CEP+GRA6II-HA transgenic
Figure 2. Immunodominance, but not immunodomination, of the GRA6II-derived HF10 peptide during chronic stage. For all panels,
B10.D2 mice were infected with the indicated parasite strains and analyzed 4 weeks post-infection. (A) Spleen cells stained ex vivo with the Ld DimerX
loaded with the GRA6II-derived HF10, ROP7-derived IF9 or GRA4-derived SM9 peptide. Each symbol represents one mouse, horizontal lines represent
the mean +/2 SEM. Data pooled from 3 independent experiments. (B) Ex vivo IFN-c intracellular staining of spleen cells restimulated with the HF10,
IF9 or SM9 peptide. Bars represent the mean +/2 SEM. Data pooled from 3 independent experiments. (C) Ex vivo Ld DimerX staining of brain-
infiltrating leukocytes. Bars represent the mean +/2 SEM. Data pooled from 2 independent experiments. (D) Ex vivo IFN-c intracellular staining of
spleen cells restimulated with J774 macrophages infected in vitro with the indicated parasites. Upper panel: mice infected with CEP+GRA6I, lower
panel: mice infected with CEP+GRA6II. Bars represent the mean +/2 SEM. Data representative from 2 independent experiments. ns: P.0.05 ; *:
P,0.05 ; **: P,0.005.
doi:10.1371/journal.ppat.1003449.g002
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Figure 3. Presence of the GRA6II-derived HF10 peptide correlates with better parasite control during acute and chronic T. gondii
infection. (A,B) BALB/c mice were infected intraperitoneally with 105 tachyzoites of the indicated parasite strains. Parasite clearance was followed
from day 7 to 13 by bioluminescence imaging on the ventral side. (A) Raw images of luminescence in pseudocolor scale. (B) Quantification of total
flux (photons/s) over time. Dots show the mean + s.d. with 3 mice per group. The differences between CEP+GRA6I and CEP+GRA6II did not achieve
statistical significance. Data representative of 2 independent experiments with at least 3 mice per condition. (C,D) B10.D2 mice were infected
intraperitoneally with 105 tachyzoites of the indicated parasite strains. (C) Parasite load in the spleen 3 weeks post-infection, as measured by the
number of cells harboring a GFP+ parasite. Bars show the mean +/2 SEM for at least 4 mice per group. The dotted line shows the background in
uninfected mice. Data pooled from 2 independent experiments. (D) Parasite burden in the brains of B10.D2 mice 4 weeks post-infection, evaluated
microscopically by enumerating the cysts. Histograms represent the mean +/2 SEM of at least 5 mice per group. Data pooled from 3 independent
experiments. ns: P.0.05 ; *: P,0.05 ; **: P,0.005.
doi:10.1371/journal.ppat.1003449.g003
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Figure 4. Immunodominance of GRA6II-derived HF10 cannot be explained by peptide affinity for L
d or naı¨ve T cell frequency. (A)
Flow cytometry surface labeling (MFI) of Ld on TAP-deficient RMA-S.Ld cells left unpulsed or pulsed with increasing concentrations of the indicated Ld-
restricted peptides or a control Dd-restricted AI9 peptide. Data representative of 3 independent assays. (B,C) Estimation of frequencies of naı¨ve T.
Epitope Location Controls Protection to T. gondii
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parasites led to similar infection rates (data not shown) but HF10
presentation was abrogated (Fig. 5C).
Finally, we examined the importance of HF10 C-terminal
location in vivo. We infected mice and analyzed the induction of
HF10-specific CD8 T cells in the spleen (Fig. 5D) and the brain
(Fig. 5E) at chronic stage. In accordance with our in vitro findings,
only the CEP+GRA6II parasites elicited a detectable HF10-
specific response. The absence of HF10-specific response in mice
infected by CEP+GRA6II-L and CEP+GRA6II-HA was consistent
with a dramatically higher cyst burden in their brains (Fig. 5F). We
conclude that the precise C-terminal location of HF10 is required
for optimal processing and presentation by T. gondii-infected APCs
and for eliciting parasite-specific T cells that could provide in vivo
protection.
Appending the SM9 peptide to the GRA6 C-terminus
overturns its subdominant status
We further assessed whether the location of an epitope at the
GRA6II C-terminus may be sufficient for enhancing presentation
and immunogenicity. We generated CEP parasites expressing the
subdominant SM9 peptide either at the C-terminus of GRA6II
(CEP+GRA6II-SM9Cter) or, as a control, internally within GRA6II
(CEP+GRA6II-SM9internal) (Fig. 6A). The selected clones ex-
pressed comparable levels of transgenes (Fig. 6B). We measured
SM9 presentation at the surface of parasite-infected cells using a
new b-galactosidase-inducible T cell hybridoma specific for Ld-
SM9 complex (BDSM9Z) (Fig. 6C). Interestingly, although the
natural SM9 precursor, GRA4, was expressed in type III parasites
(data not shown), the presentation of Ld-SM9 complexes remained
below detection in CEP-infected BMDMs. SM9 presentation was
also undetectable when the peptide was placed at an internal
position within GRA6. In contrast, BDSM9Z T cells were strongly
stimulated when SM9 was located at GRA6 C-terminus (Fig. 6C).
HF10 presentation by infected BMDMs was abrogated by the
presence of SM9 at the C-terminus but not by the presence of
SM9 at the internal position (Fig. 6D), consistent the C-terminal
extension studies described above (Fig. 5C),. In conclusion, placing
the SM9 peptide at the C-terminus of GRA6II was sufficient to
enhance its presentation by parasite-infected cells in vitro.
We next measured the SM9 and HF10-specific CD8 T cell
responses in the spleen (Fig. 6E) and brain (Fig. 6F) of mice
infected for 3 weeks with the transgenic parasites. A SM9-specific
response was hardly detectable in mice infected with the control
CEP. Infection with CEP+GRA6II-SM9internal elicited SM9-
specific CD8 T cells but these T cells were between 3-fold (spleen,
Fig. 6E) and 5-fold (brain, Fig. 6F) more abundant when SM9 was
grafted at GRA6 C-terminus. This difference was not due to
reduced infectivity of the CEP+GRA6II-SM9internal parasites since
HF10-specific CD8 T cells were abundant in those mice
(Fig. 6E,F). Similar results were obtained in mice immunized with
irradiated tachyzoites (Fig. S6 in Text S1). To ask whether the
enhanced SM9-specific response participates in parasite control,
we enumerated the brain cysts in the 3 groups. As compared to
mice infected with control CEP, the parasite load was lower when
either a strong HF10- or a strong SM9-specific response was
elicited (Fig. 6G). These data indicate that the nature of the
antigenic peptide itself does not seem to determine the protective
effect. We conclude that location of a subdominant peptide at
GRA6 C-terminus dramatically enhanced its immunogenicity,
changed the epitope hierarchy and had beneficial repercussions for
parasite control.
Discussion
In this study, we have identified the molecular bases underlying
the marked immunodominance of a CD8 T cell response that
controls the intracellular T. gondii parasite. Rather than peptide
affinity for MHC I and naı¨ve T cell frequency, we find that
immunodominance is determined by the location of the epitope
within the antigenic precursor.
The endeavor to characterize natural T cell antigens from T.
gondii has started only recently [17,20,26,27] but it has provided
much needed tools to better understand T cell immunity to this
widespread opportunistic pathogen. We report here that the 3
known Ld-restricted responses follow an immunodominance
hierarchy. At chronic stage, GRA6II-specific CD8 T cells were
between 10-fold (in the spleen) and 30-fold (in the brain) more
abundant than CD8 T cells specific for the 2nd dominant epitope:
IF9 derived from ROP7. Response to the 3rd dominant epitope,
SM9 derived from GRA4, was hardly detectable. Remarkably, we
did not observe immunodomination by the GRA6II dominant
epitope. Immunodomination refers to situations in which the T
cell response to a given epitope is inhibited by T cells specific for
another, more dominant, epitope [2]. This phenomenon has been
reported during infection by simian immunodeficiency virus [28]
and by Trypanosoma cruzi, another protozoan parasite phylogenet-
ically related to T. gondii [29]. A mechanism commonly proposed
to explain immunodomination is elimination of APCs by the
dominant cytotoxic T cells. Perhaps immunodomination does not
occur here because, as compared to IFN-c production, perforin-
mediated cytolysis by CD8 T cells plays only a limited role during
T. gondii infection [30]. The absence of immunodomination also
suggests that accessibility of peptide-loaded APCs for T cells is not
limiting. This may be because T. gondii is able to invade and be
presented on MHC I by many cell types, even non-professional
APCs [31].
Another major conclusion is that during chronic stage,
subdominant responses could not compensate and provide
efficient parasite control in the absence of the GRA6II dominant
peptide. These data designate GRA6 as a strain-specific compo-
nent which determines chronic parasitemia and is targeted by
adaptive immunity. This is in contrast to already known T. gondii
virulence factors which mostly interfere with innate processes, such
as ROP16 which interferes with STAT transcription factors [32],
ROP18 which disarms immunity-related GTPases involved in host
defense [33,34]) or GRA15 which promotes NF-kB activation
[35]. Of note, GRA6 is among the 20 most polymorphic genes in
the T. gondii genome and many polymorphisms are located in its
C-terminal region (see ToxoDB.org and Fig. S1 in Text S1).
Beyond the 3 prototypic strains, sequence polymorphisms in
GRA6 have been characterized in more exotic strains (or
haplogroups) [36]. These atypical strains either express HF10,
HY10 or alternative versions of the decamer peptide with distinct
polymorphisms. Interestingly, in chronically infected humans,
some of these variations are specifically recognized by natural
gondii-specific CD8a+ T cell populations in naive B10.D2 mice. (B) Representative flow plots of T cells isolated from spleen and lymph nodes of
uninfected mice. Shown are CD62L and tetramer (SM9:Ld, IF9:Ld or HF10:Ld) stainings after gating on live dump2 (dump = B220, F4/80, MHC II) CD3+
CD8a+ T cells. One million events were collected for each sample. (C) Summary of total tetramer+ T cells per mouse. Each dot represents one mouse.
Pooled data from 3 independent experiments. Mean +/2 SEM are represented by horizontal lines and values are noted on the graph. *: P,0.05 ; **:
P,0.005.
doi:10.1371/journal.ppat.1003449.g004
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Figure 5. Optimal presentation and parasite control depend on the location of HF10 at the C-terminus of GRA6. (A) HF10 presentation
assessed with the CTgEZ.4 hybridomas on mouse fibroblasts co-transfected with Ld and plasmids coding for the indicated C-terminally-extended
GRA6II. Graph shows percentages of maximal response, obtained with 5 ng of wild-type GRA6II plasmid/well. Data are averaged from 2 independent
assays +/2 SEM. (B) Western blot analysis of GRA6 (upper panels), HA (middle panels) and SAG1 (loading control, lower panels) of the indicated
parasites. (C) HF10 presentation by BMDMs infected for 24 h with the indicated parasites, assessed with the CTgEZ.4 hybridomas. Representative of 4
independent experiments. (D,E) Ex vivo HF10:Ld DimerX staining of spleen cells (D) and brain-infiltrating leukocytes (E) from 3–4 week-infected B10.D2
Epitope Location Controls Protection to T. gondii
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antibodies that are used as a tool to serotype the parasite [37,38].
Given that GRA6 C-terminus is targeted both by humoral and
cellular responses, we speculate that selective pressure by adaptive
immunity may have contributed in shaping GRA6 polymor-
phisms.
By exploring the possible causes of HF10 immunodominance,
we were able to rule out two possible explanations. We found no
positive correlation of immunodominance hierarchy with peptide
affinity for Ld or naı¨ve T cell frequency. The numbers of naı¨ve
HF10- and IF9-specific T cells fall within the previously reported
range of 15 to 1500 naı¨ve CD8 T cells per mouse [39] but the
number of SM9-specific cells (4300) may look unusually high.
Although the exact reason remains unclear, this may be related to
a large amount of positive selecting ligands available for this
population. In agreement with this idea, an F1 H2bxd mouse strain
gives half the value measured with the B10.D2 H-2d strain (data
not shown). Remarkably, we found an inverse correlation between
size of the naı¨ve population and magnitude of the parasite-specific
response. This latter result may seem paradoxical in the light of
other situations, such as peptide immunization [23] or viral
infection [7,9,10,24], where size of the naı¨ve pool was a good
predictor of immunodominance. However, there are known
exceptions to this rule [12]. Here, the low abundance of HF10-
specific precursors may facilitate their expansion by limiting
interclonal competition. Alternatively, the TCRs used by HF10-
specific CD8 T cells may have a high affinity for the HF10-Ld
complex, which could promote stronger signaling and prolifera-
tion. These hypotheses remain to be investigated.
Our central finding is that C-terminal position of the epitope
within GRA6 plays a crucial role for immunodominance. It is
illustrated by the fact that the weakly immunogenic GRA4 epitope
elicited strong SM9-specific responses when grafted at GRA6 C-
terminus. Intriguingly, the internal position of SM9 gave rise to a
lower, but substantial, CD8 response whereas we did not detect
any HF10-specific T cells when HF10 was placed at the same
internal position (Fig. S7 in Text S1). The bases for such a different
outcome are unknown but they may lie in different epitope-
dependent processing efficiencies or compensatory effects of the
high frequency of SM9-specific T cell precursors counteracting the
less favorable position for processing. Most notably, addition of
residues to GRA6II C-terminus greatly impaired presentation. It is
theoretically possible that the C-terminal flanking sequences
abrogated HF10 presentation by altering the vacuolar trafficking
of GRA6 and/or its membrane insertion. We think it is unlikely
because 1) we found that transport of GRA6II-HA was
undistinguishable from transport of total GRA6 and 2) presenta-
tion of the C-terminal SM9 peptide could occur efficiently in vitro
and in vivo. Rather than regulating global GRA6 trafficking, we
favor the idea that additional C-terminal sequences impair
processing. Epitope-flanking sequences are indeed known to
positively or negatively affect protease cleavage capacity and
generation of the final peptide, with clear consequences on
immunodominance [4,6,40,41,42]. Using minigenes, it was shown
that the nature of C-terminal flanking residues profoundly impacts
excision of the processed peptide [42]. In the context of a full-
length viral protein, single changes to the epitope-flanking residues
dramatically reduced presentation [41] and it was later proposed
that the subdominant nature of certain peptides bearing appro-
priate consensus motifs might result from suboptimal C-terminal
sequences [40]. Finally, it is interesting to note that the influence of
the flanking motifs may differ whether the antigen is presented by
the direct MHC I pathway or by cross-presentation [43]. In our
case, we observed a dramatic impact of the absence or presence of
C-terminal residues on presentation, suggesting a key role for
antigen processing in modulating immunodominance. A system-
atic screening of C-terminal extensions may be useful to precisely
define the rules that govern processing of GRA6 C-terminus.
Since GRA6 behaves as an integral transmembrane protein in
the vacuole [44], the importance of the C-terminus could be
related to the topology of GRA6 membrane insertion. One
possibility is that GRA6 C-terminal domain is displayed in the
cytosol and thus potentially accessible to host proteases. This
mechanism was proposed for antigens from the intravacuolar
bacteria Chlamydia trachomatis that are inserted in the surrounding
membrane of the bacteria-containing vacuole [45,46]. This
hypothesis remains to be tested. Alternatively, unfolded GRA6
may access the cytosol thanks to the recruitment of host
endoplasmic reticulum components on the parasitophorous
vacuole, as proposed for the soluble OVA model antigen
[47,48]. In any case, we consider it likely that access of GRA6
to the MHC I pathway is less efficient than in the situation of a
viral antigen directly synthesized by the host cell translation
machinery. Consequently, any parameter that would facilitate
processing (e.g. being at C-terminus) may become the determining
factor for the presentation outcome.
To our knowledge, this is the first evidence that C-terminal
position can be positively correlated with immunodominance.
Given the variety of parameters that can influence immunodomi-
nance, a remaining question is the degree of peculiarity of our
current findings with respect to other antigens. A recent study
interrogating the Immune Epitope Database (www.iedb.org) for a
positional bias of viral epitopes reported that epitopes from both
ends of a protein tended to be underrepresented [49]. An indirect
way to assess the general relevance of the C-terminal position
would be to transfer subdominant epitopes to the C-terminus of
their respective antigens (e.g. GRA4, ROP7) and evaluate the
impact on CD8 responses. Future studies, not only with T. gondii
but also with other intracellular parasites, should shed light on the
general relevance of this position.
During T. gondii infection in vivo, two scenarios of MHC I
presentation could co-exist. On the one hand, phagocytosed
parasite material may be processed by bystander cells present in
the vicinity of infected cells [50]. On the other hand, parasite
proteins may be directly presented by actively infected cells [51].
Our work shows that antigen access to the MHC I pathway and
efficient processing are the limiting factors that control immuno-
dominance. Beyond amino acid mutations within the peptide
sequence, modifying the epitope position may provide the parasite
with a strategy to manipulate how it is detected by CD8 T cells.
Understanding the features that make certain peptides immuno-
genic will shed light on the strategies used by parasites to interact
with their host immune system.
Materials and Methods
Ethics statement
In the US, animal studies were carried out in accordance with
the recommendations of the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health and in
compliance with the guidelines of the Institutional Animal Care
mice. Each dot represents one mouse, bars show the mean +/2 SEM. Data pooled from 2 independent experiments. (F) Cyst burden in the brains of
B10.D2 mice infected for 4 weeks. Data pooled from 3 independent experiments. **: P,0.005.
doi:10.1371/journal.ppat.1003449.g005
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and Use Committee (IACUC) of the University of California. The
animal protocols were approved by the IACUC of the University
of California, Berkeley (Animal Use Protocol # R057-0913BR)
and of the University of Pittsburgh, PA (Protocol # 1210130). In
France, animal studies were carried out under the control of the
National Veterinary Services and in accordance with European
regulations (EEC directive 86/609 dated 24 November 1986). The
protocol was approved by the Regional Ethics Committee from
the Midi-Pyre´ne´es Region (Approval # MP/01/29/09/10).
Mice and parasites
C57BL/6J (B6), BALB/c and B10.D2-Hc1 H2d H2-T18c/
nSnJ (B10.D2) mice were purchased from The Jackson Laboratory
(Bar Harbor, ME, USA). B6xDBA/2 F1 (B6D2) mice were
purchased from Charles River (France). For all experiments, sex
and age-matched mice were used. Mice were handled with the
approval of local ethics committees. Except for the CEP+GRA6II-
HA clone which was a gift from J. Saeij (Cambridge, MA, USA),
all transgenic parasites were generated from the parental
CEP.DHXGPRT.GFP.Luc strain [22]. Tachyzoites were main-
tained by passage on confluent monolayers of human foreskin
fibroblasts (HFF). For infections, parasites were harvested, filtered
through 3 mm and 105 tachyzoites were injected intraperitoneally
in 100 ml PBS.
Plasmid constructs, parasite and L cell transfection
For in vitro expression of antigenic sequences, all C-terminally
extended GRA6II sequences were cloned into the pcDNA1 vector
containing the pcDNA1-embedded 39UTR. Plasmids used for T.
gondii transfection were derived from the pGRA.HA.HPT vector, a
gift from J.D. Dunn and J. Boothroyd (Palo Alto, CA, USA). More
details on the construction of the plasmids are given in the
Supporting Protocol S1 in Text S1.
L cells were triple transfected using a standard diethylami-
noethyl dextran method with vectors coding for Ld, B7-2 and
mutant GRA6, as previously described [17]. For parasite
transfections, 1.56107 tachyzoites were electroporated with
50 mg of HindIII-linearized plasmid DNA and inoculated in 4
confluent HFF flasks in order to obtain up to 4 independent
clones. The next day, 25 mg/ml mycophenolic acid and 50 mg/ml
xanthine were added for selection. After 2 passages, resistant
tachyzoites were cloned by limiting dilution and presence of the
transgene was verified by PCR. For each construct, one clone that
acquired resistance but no transgene was kept as HXGPRT+
control.
MHC I stabilization assay
RMA-S.Ld cells were a gift from T. Hansen (St-Louis, MO,
USA). RMA-S.Ld cells were incubated at 37uC, 5% CO2 for 8 h
to saturate the culture medium with CO2. The flask was sealed
with parafilm and incubated at RT overnight. The next day, cells
were washed with PBS and plated at 36105 cells/well in a 96-W
plate. Peptide was added to the cells in serial dilutions. The plate
was incubated for 1 h at RT and 3 h at 37uC. Cells were stained
with the 30-5-7 antibody (specific for conformed, peptide-bound
Ld) and a phycoerythrine (PE)-coupled goat anti-mouse secondary
antibody and analyzed by flow cytometry.
Western blot
HFFs were disrupted with a 23-G needle and tachyzoites were
lysed in a lysis buffer containing 1% NP-40, 10 mM Tris pH 7.4,
150 mM NaCl, and protease inhibitors (cOmplete EDTA-free,
Roche) for 30 min on ice. Lysates were centrifuged for 15 min at
15,000 g. Solubilized proteins were boiled and reduced for 5 min
in SDS sample buffer, separated by electrophoresis on 12%
polyacrylamide gels and transferred to nitrocellulose membranes.
Immunologic detection was achieved using rabbit anti-GRA6
serum (gift from L. D. Sibley, St-Louis, MO, USA), mouse anti-
HA (gift from D. Raulet, UC Berkeley, CA, USA) or mouse anti-
SAG1 (clone TP3, Santa Cruz) followed by secondary horseradish-
peroxidase-conjugated antibodies. Peroxidase activity was visual-
ized by chemiluminescence.
Ex vivo cell preparations
Mice were sacrificed 3 to 4 weeks after infection. Spleens were
dissociated into single-cell suspensions in complete RPMI (In-
vitrogen) supplemented with 10% (vol/vol) FCS (Hyclone).
Samples were depleted of erythrocytes with ACK lysis buffer
(100 mM EDTA, 160 mM NH4Cl and 10 mM NaHCO3).
Leukocytes from the brain were prepared as in [17]. In brief,
brains were minced and digested for 1 h at 37uC with 1 mg/ml
collagenase (Sigma) and 100 mg/ml DNAseI (Roche) in complete
RPMI. Brain suspensions were filtered through 70-mm cell
strainers and centrifuged for 10 min at 200 g. Cells were
resuspended in 60% (vol/vol) Percoll (GE Healthcare), overlaid
on 30% (vol/vol) Percoll and centrifuged 20 min at 1,000 g.
Infiltrating mononuclear cells were collected from the gradient
interface and the remaining erythrocytes were lyzed with ACK
lysis buffer.
Parasite load analysis
The number of infected splenocytes was determined by
measuring the percentage of GFP+ cells by flow cytometry.
Results from two samples with over 26105 events collected per
tube were averaged for each mouse. For cyst enumeration, the
brain was homogenized over a 100 mm strainer and 5% of the
entire brain was stained with fluorescein-conjugated Dolichos biflorus
agglutinin (Vector Laboratories). Cysts were counted using an
inverted fluorescence microscope. For bioluminescence imaging,
BALB/c mice were infected intraperitoneally with 105 tachyzoites
Figure 6. Grafting subdominant SM9 at GRA6II C-terminus enhances its presentation, overturns the dominance hierarchy and
provides efficient cyst control. (A) Schematic description of the GRA6II-SM9 chimeric constructs. For GRA6II-SM9Cter, SM9 was introduced at the C-
terminus, downstream of HF10. For GRA6II-SM9internal, SM9 was introduced internally within GRA6II after residue 153, before the putative
transmembrane domain. In both cases, SM9 was preceded by a leucine to mimic the endogenous flanking sequence of HF10. (B) Western blot
analysis of GRA6 (upper panels) and SAG1 (loading control, lower panels) of the indicated parasite clones. (C,D) SM9 and HF10 presentation by
BMDMs infected for 24 h with the indicated parasites, assessed with the BDSM9Z (C) and CTgEZ.4 (D) hybridomas, respectively. (E,F,G) Ex vivo
evaluation of the CD8 responses and the parasite load 3 weeks post-infection with the indicated parasites. (E) IFN-c intracellular staining of spleen
cells restimulated with the SM9 peptide (left panel) or the HF10 peptide (right panel). (F) Tetramer staining of brain cells with SM9:Ld (left panel) and
HF10:Ld (right panel). Bars represent the mean +/2 SEM. Data pooled from 2 independent experiments. (G) Parasite burden in the brains of mice
infected with control CEP (white bar), CEP+GRA6II-SM9internal (black bar) or CEP+GRA6II-SM9Cter (hatched bar), evaluated microscopically by
enumerating the cysts. Histograms represent the mean +/2 SEM of 14 mice per group, pooled from 3 independent experiments. *: P,0.05 ; **:
P,0.005.
doi:10.1371/journal.ppat.1003449.g006
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of CEP expressing GRA6I or GRA6II or control CEP HXGPRT
+.
Parasite burden was assessed using in vivo bioluminescence imaging
as described previously [52]. Briefly, daily readings were
performed using an IVIS Lumina II imaging system (Caliper).
Ten minutes prior to imaging, mice were injected intraperitoneally
with 200 mL of 15.4 mg/mL D-Luciferin in PBS and anesthetized
using 2% isoflurane. Dorsal and ventral images were acquired for
5 minutes and luminescence (photons/s/cm2/sr, total flux ex-
pressed as photons/s) was quantified using IgorPro Image Analysis
Software (Caliper).
Primary macrophage differentiation
Bone marrow cells were obtained from mouse femurs and tibias.
Primary BMDMs were differentiated for 7 days in Petri dishes
with RPMI supplemented with 20% (vol/vol) FCS and 10% (vol/
vol) colony-stimulating factor–containing culture supernatant
(purity, about 95% CD11b+). Colony-stimulating factor-producing
3T3 cells were a gift from R. Vance (UC Berkeley, CA, USA).
BMDMs were infected for 24 h with c-irradiated tachyzoites (120
Gy) at various multiplicities of infection and used in antigen
presentation assays. In all experiments, the proportion of infected
(GFP+) BMDMs was controlled by flow cytometry.
Generation of T cell hybridomas and antigen
presentation assays
B6D2 F1 mice were immunized subcutaneously with 100 mg
synthetic SM9 peptide in complete Freund’s adjuvant and boosted
after 2 weeks. One week later, spleens were harvested and
restimulated with 10 nM SM9. Recombinant human IL-2 (50 U/
ml) and 5% T-stim (both from BD Pharmingen) were added after
day 2 to support CD8 T cell proliferation. Four days after
restimulation, responding cells were fused to the TCRab-negative
lacZ-inducible BWZ.36/CD8a fusion partner as described in [17].
Specificity of the resulting BDSM9Z hybridomas was tested by
overnight incubation with peptide-pulsed or unpulsed Ld-transfected
L cells. TCR-mediated stimulation of the BDSM9Z and the
CTgEZ.4 hybridomas [17] was quantified using a chromogenic
substrate: chlorophenol red-b-D-galactopyranoside (CPRG, Roche).
Cleavage of the CPRG by b-galactosidase releases a purple product,
which absorbance was read at 595 nm with a reference at 655 nm.
Naı¨ve T cell enumeration and flow cytometry
Spleen and major lymph nodes from individual naı¨ve B10.D2
mice were harvested. Single cell suspension was stained with PE-
labeled (Prozyme) SM9:Ld, IF9:Ld or HF10:Ld tetramers (NIH
tetramer facility). Tetramer enrichment was performed on each
sample with anti-PE magnetic beads (Miltenyi Biotec) and each
sample was stained with antibodies (BD Biosciences) for flow
cytometry analysis. Total numbers of CD8a+tetramer+ T cells per
mouse were determined as before [23,24].
For other stainings, surfaces were labeled according to standard
procedures with flow cytometry buffer (3% (vol/vol) FCS and
1 mM EDTA in PBS). Intracellular IFN-c was detected with the
Cytofix/Cytoperm kit (BD Pharmingen). DimerX H-2Ld:Ig
(fusion protein of H-2Ld and immunoglobulin; BD Biosciences)
was used according to the manufacturer’s instructions and as
described in [17]. All flow cytometry data were acquired on an XL
Analyzer (Coulter) or a LSRII (Becton Dickinson) and were
analyzed with FlowJo software (Tree Star).
Statistical analysis
Prism software (GraphPad) was used for statistical analyses. All
P values were calculated with the two-tailed Mann-Whitney test
(nonparametric).
Supporting Information
Text S1 Text S1 contains the Supporting Figures S1 to S7 and
their respective legends, the: experimental procedures used for the
generation of plasmid constructs, the mouse immunizations and
immunofluorescence as Supporting protocol S1 and the references
cited in the Supporting Figure legends as Supporting References S1.
(DOCX)
Acknowledgments
J. Boothroyd, J.D. Dunn, T. Hansen, D. Raulet, J. Saeij, L.D. Sibley, R.
Vance for reagents, NIH tetramer core facility for the tetramers, C.
Mercier, M.-F. Delauw for reagents and helpful discussions, J. Lopez and
the Blanchard team for technical help and discussions, C. Bonnart, D.
Dunia, R. Lesourne for critical reading of the manuscript.
Author Contributions
Conceived and designed the experiments: VF VV HHC JPB EAR NS NB.
Performed the experiments: VF VV HSG HHC MJB JW JPB NB.
Analyzed the data: VF HSG VV HHC MJB JW JPB EAR NS NB. Wrote
the paper: NB.
References
1. van Endert P (2011) Providing ligands for MHC class I molecules. Cellular and
molecular life sciences : CMLS 68: 1467–1469.
2. Chen W, McCluskey J (2006) Immunodominance and immunodomination:
critical factors in developing effective CD8+ T-cell-based cancer vaccines. Adv
Cancer Res 95: 203–247.
3. Yewdell JW (2006) Confronting complexity: real-world immunodominance in
antiviral CD8+ T cell responses. Immunity 25: 533–543.
4. Tenzer S, Wee E, Burgevin A, Stewart-Jones G, Friis L, et al. (2009) Antigen
processing influences HIV-specific cytotoxic T lymphocyte immunodominance.
Nat Immunol 10: 636–646.
5. Blanchard N, Kanaseki T, Escobar H, Delebecque F, Nagarajan NA, et al.
(2010) Endoplasmic reticulum aminopeptidase associated with antigen process-
ing defines the composition and structure of MHC class I peptide repertoire in
normal and virus-infected cells. J Immunol 184: 3033–3042.
6. Le Gall S, Stamegna P, Walker BD (2007) Portable flanking sequences modulate
CTL epitope processing. J Clin Invest 117: 3563–3575.
7. La Gruta NL, Kedzierska K, Pang K, Webby R, Davenport M, et al. (2006) A
virus-specific CD8+ T cell immunodominance hierarchy determined by antigen
dose and precursor frequencies. Proceedings of the National Academy of
Sciences of the United States of America 103: 994–999.
8. Crowe SR, Turner SJ, Miller SC, Roberts AD, Rappolo RA, et al. (2003)
Differential antigen presentation regulates the changing patterns of CD8+ T cell
immunodominance in primary and secondary influenza virus infections. J Exp
Med 198: 399–410.
9. Kotturi MF, Scott I, Wolfe T, Peters B, Sidney J, et al. (2008) Naive precursor
frequencies and MHC binding rather than the degree of epitope diversity shape
CD8+ T cell immunodominance. J Immunol 181: 2124–2133.
10. Tan AC, La Gruta NL, Zeng W, Jackson DC (2011) Precursor Frequency and
Competition Dictate the HLA-A2-Restricted CD8+ T Cell Responses to
Influenza A Infection and Vaccination in HLA-A2.1 Transgenic Mice.
J Immunol 187: 1895–1902.
11. St Leger AJ, Peters B, Sidney J, Sette A, Hendricks RL (2011) Defining the
herpes simplex virus-specific CD8+ T cell repertoire in C57BL/6 mice.
J Immunol 186: 3927–3933.
12. La Gruta NL, Rothwell WT, Cukalac T, Swan NG, Valkenburg SA, et al.
(2010) Primary CTL response magnitude in mice is determined by the extent of
naive T cell recruitment and subsequent clonal expansion. J Clin Invest 120:
1885–1894.
13. Dolan BP, Bennink JR, Yewdell JW (2011) Translating DRiPs: progress in
understanding viral and cellular sources of MHC class I peptide ligands. Cellular
and molecular life sciences : CMLS 68: 1481–1489.
14. Blanchard N, Shastri N (2010) Cross-presentation of peptides from intracellular
pathogens by MHC class I molecules. Annals of the New York Academy of
Sciences 1183: 237–250.
Epitope Location Controls Protection to T. gondii
PLOS Pathogens | www.plospathogens.org 13 June 2013 | Volume 9 | Issue 6 | e1003449
15. Kumar KA, Sano G, Boscardin S, Nussenzweig RS, Nussenzweig MC, et al.
(2006) The circumsporozoite protein is an immunodominant protective antigen
in irradiated sporozoites. Nature 444: 937–940.
16. MacHugh ND, Weir W, Burrells A, Lizundia R, Graham SP, et al. (2011)
Extensive polymorphism and evidence of immune selection in a highly dominant
antigen recognized by bovine CD8 T cells specific for Theileria annulata. Infect
Immun 79: 2059–2069.
17. Blanchard N, Gonzalez F, Schaeffer M, Joncker NT, Cheng T, et al. (2008)
Immunodominant, protective response to the parasite Toxoplasma gondii
requires antigen processing in the endoplasmic reticulum. Nat Immunol 9: 937–
944.
18. Montoya JG, Liesenfeld O (2004) Toxoplasmosis. Lancet 363: 1965–1976.
19. Johnson JJ, Roberts CW, Pope C, Roberts F, Kirisits MJ, et al. (2002) In vitro
correlates of Ld-restricted resistance to toxoplasmic encephalitis and their critical
dependence on parasite strain. J Immunol 169: 966–973.
20. Frickel EM, Sahoo N, Hopp J, Gubbels MJ, Craver MP, et al. (2008) Parasite
stage-specific recognition of endogenous Toxoplasma gondii-derived CD8+ T
cell epitopes. J Infect Dis 198: 1625–1633.
21. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999)
SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics
50: 213–219.
22. Kamau E, Meehan T, Lavine MD, Arrizabalaga G, Mustata Wilson G, et al.
(2011) A novel benzodioxole-containing inhibitor of Toxoplasma gondii growth
alters the parasite cell cycle. Antimicrobial agents and chemotherapy 55: 5438–
5451.
23. Moon JJ, Chu HH, Pepper M, McSorley SJ, Jameson SC, et al. (2007) Naive
CD4(+) T cell frequency varies for different epitopes and predicts repertoire
diversity and response magnitude. Immunity 27: 203–213.
24. Obar JJ, Khanna KM, Lefrancois L (2008) Endogenous naive CD8+ T cell
precursor frequency regulates primary and memory responses to infection.
Immunity 28: 859–869.
25. Gendrin C, Bittame A, Mercier C, Cesbron-Delauw MF (2010) Post-
translational membrane sorting of the Toxoplasma gondii GRA6 protein into
the parasite-containing vacuole is driven by its N-terminal domain. Int J Parasitol
40: 1325–1334.
26. Wilson DC, Grotenbreg GM, Liu K, Zhao Y, Frickel EM, et al. (2010)
Differential regulation of effector- and central-memory responses to Toxoplasma
gondii Infection by IL-12 revealed by tracking of Tgd057-specific CD8+ T cells.
PLoS Pathog 6: e1000815.
27. Grover HS, Blanchard N, Gonzalez F, Chan S, Robey EA, et al. (2012) The
Toxoplasma gondii Peptide AS15 Elicits CD4 T Cells That Can Control
Parasite Burden. Infect Immun 80: 3279–3288.
28. Newberg MH, McEvers KJ, Gorgone DA, Lifton MA, Baumeister SH, et al.
(2006) Immunodomination in the evolution of dominant epitope-specific CD8+
T lymphocyte responses in simian immunodeficiency virus-infected rhesus
monkeys. J Immunol 176: 319–328.
29. Tzelepis F, de Alencar BC, Penido ML, Claser C, Machado AV, et al. (2008)
Infection with Trypanosoma cruzi restricts the repertoire of parasite-specific
CD8+ T cells leading to immunodominance. J Immunol 180: 1737–1748.
30. Wang X, Kang H, Kikuchi T, Suzuki Y (2004) Gamma interferon production,
but not perforin-mediated cytolytic activity, of T cells is required for prevention
of toxoplasmic encephalitis in BALB/c mice genetically resistant to the disease.
Infect Immun 72: 4432–4438.
31. Dzierszinski F, Pepper M, Stumhofer JS, LaRosa DF, Wilson EH, et al. (2007)
Presentation of Toxoplasma gondii antigens via the endogenous major
histocompatibility complex class I pathway in nonprofessional and professional
antigen-presenting cells. Infect Immun 75: 5200–5209.
32. Saeij JP, Coller S, Boyle JP, Jerome ME, White MW, et al. (2007) Toxoplasma
co-opts host gene expression by injection of a polymorphic kinase homologue.
Nature 445: 324–327.
33. Steinfeldt T, Konen-Waisman S, Tong L, Pawlowski N, Lamkemeyer T, et al.
(2010) Phosphorylation of Mouse Immunity-Related GTPase (IRG) Resistance
Proteins Is an Evasion Strategy for Virulent Toxoplasma gondii. PLoS Biol 8:
e1000576.
34. Fentress SJ, Behnke MS, Dunay IR, Mashayekhi M, Rommereim LM, et al.
(2010) Phosphorylation of Immunity-Related GTPases by a Toxoplasma gondii-
Secreted Kinase Promotes Macrophage Survival and Virulence. Cell Host
Microbe 8: 484–495.
35. Rosowski EE, Lu D, Julien L, Rodda L, Gaiser RA, et al. (2011) Strain-specific
activation of the NF-kappaB pathway by GRA15, a novel Toxoplasma gondii
dense granule protein. J Exp Med 208: 195–212.
36. Sousa S, Ajzenberg D, Marle M, Aubert D, Villena I, et al. (2009) Selection of
polymorphic peptides from GRA6 and GRA7 sequences of Toxoplasma gondii
strains to be used in serotyping. Clinical and vaccine immunology : CVI 16:
1158–1169.
37. Peyron F, Lobry JR, Musset K, Ferrandiz J, Gomez-Marin JE, et al. (2006)
Serotyping of Toxoplasma gondii in chronically infected pregnant women:
predominance of type II in Europe and types I and III in Colombia (South
America). Microbes Infect 8: 2333–2340.
38. Kong JT, Grigg ME, Uyetake L, Parmley S, Boothroyd JC (2003) Serotyping of
Toxoplasma gondii infections in humans using synthetic peptides. J Infect Dis
187: 1484–1495.
39. Jenkins MK, Moon JJ (2012) The role of naive T cell precursor frequency and
recruitment in dictating immune response magnitude. Journal of immunology
188: 4135–4140.
40. Mo AX, van Lelyveld SF, Craiu A, Rock KL (2000) Sequences that flank
subdominant and cryptic epitopes influence the proteolytic generation of MHC
class I-presented peptides. J Immunol 164: 4003–4010.
41. Yellen-Shaw AJ, Wherry EJ, Dubois GC, Eisenlohr LC (1997) Point mutation
flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length
viral protein. J Immunol 158: 3227–3234.
42. Shastri N, Serwold T, Gonzalez F (1995) Presentation of endogenous peptide/
MHC class I complexes is profoundly influenced by specific C-terminal flanking
residues. Journal of immunology 155: 4339–4346.
43. Ma X, Serna A, Xu RH, Sigal LJ (2009) The amino acid sequences flanking an
antigenic determinant can strongly affect MHC class I cross-presentation
without altering direct presentation. J Immunol 182: 4601–4607.
44. Labruyere E, Lingnau M, Mercier C, Sibley LD (1999) Differential membrane
targeting of the secretory proteins GRA4 and GRA6 within the parasitophorous
vacuole formed by Toxoplasma gondii. Mol Biochem Parasitol 102: 311–324.
45. Blanchard N, Shastri N (2010) Topological journey of parasite-derived antigens
for presentation by MHC class I molecules. Trends in immunology 31: 414–421.
46. Starnbach MN, Loomis WP, Ovendale P, Regan D, Hess B, et al. (2003) An
inclusion membrane protein from Chlamydia trachomatis enters the MHC class
I pathway and stimulates a CD8+ T cell response. J Immunol 171: 4742–4749.
47. Cebrian I, Visentin G, Blanchard N, Jouve M, Bobard A, et al. (2011) Sec22b
regulates phagosomal maturation and antigen crosspresentation by dendritic
cells. Cell 147: 1355–1368.
48. Goldszmid RS, Coppens I, Lev A, Caspar P, Mellman I, et al. (2009) Host ER-
parasitophorous vacuole interaction provides a route of entry for antigen cross-
presentation in Toxoplasma gondii-infected dendritic cells. J Exp Med 206: 399–
410.
49. Kim Y, Yewdell JW, Sette A, Peters B (2013) Positional Bias of MHC Class I
Restricted T-Cell Epitopes in Viral Antigens Is Likely due to a Bias in
Conservation. PLoS computational biology 9: e1002884.
50. John B, Harris TH, Tait ED, Wilson EH, Gregg B, et al. (2009) Dynamic
Imaging of CD8(+) T cells and dendritic cells during infection with Toxoplasma
gondii. PLoS pathogens 5: e1000505.
51. Gubbels MJ, Striepen B, Shastri N, Turkoz M, Robey EA (2005) Class I major
histocompatibility complex presentation of antigens that escape from the
parasitophorous vacuole of Toxoplasma gondii. Infect Immun 73: 703–711.
52. Boyle JP, Saeij JP, Boothroyd JC (2007) Toxoplasma gondii: inconsistent
dissemination patterns following oral infection in mice. Experimental parasitol-
ogy 116: 302–305.
Epitope Location Controls Protection to T. gondii
PLOS Pathogens | www.plospathogens.org 14 June 2013 | Volume 9 | Issue 6 | e1003449
